Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients
Abstract The aim of this study was to evaluate the association of circulating lymphocytes profiling with antibody response in cancer patients receiving the third dose of COVID-19 mRNA-BNT162b2 vaccine. Immunophenotyping of peripheral blood was used to determine absolute counts of lymphocyte subsets,...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-12-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-25558-8 |
| _version_ | 1797977441283604480 |
|---|---|
| author | Enzo Maria Ruggeri Fabrizio Nelli Diana Giannarelli Agnese Fabbri Julio Rodrigo Giron Berrios Antonella Virtuoso Eleonora Marrucci Marco Mazzotta Marta Schirripa Carlo Signorelli Mario Giovanni Chilelli Francesca Primi Cristina Fiore Valentina Panichi Giuseppe Topini Maria Assunta Silvestri |
| author_facet | Enzo Maria Ruggeri Fabrizio Nelli Diana Giannarelli Agnese Fabbri Julio Rodrigo Giron Berrios Antonella Virtuoso Eleonora Marrucci Marco Mazzotta Marta Schirripa Carlo Signorelli Mario Giovanni Chilelli Francesca Primi Cristina Fiore Valentina Panichi Giuseppe Topini Maria Assunta Silvestri |
| author_sort | Enzo Maria Ruggeri |
| collection | DOAJ |
| description | Abstract The aim of this study was to evaluate the association of circulating lymphocytes profiling with antibody response in cancer patients receiving the third dose of COVID-19 mRNA-BNT162b2 vaccine. Immunophenotyping of peripheral blood was used to determine absolute counts of lymphocyte subsets, alongside detection of IgG antibodies against receptor-binding-domain (RBD) of the SARS-CoV-2 Spike protein (S1) before booster dosing (timepoint-1) and four weeks afterward (timepoint-2). An IgG titer ≥ 50 AU/mL defined a positive seroconversion response. An IgG titer ≥ 4446 AU/mL was assumed as a correlate of 50% vaccine efficacy against symptomatic infections. A total of 258 patients on active treatment within the previous six months were enrolled between September 23 and October 7, 2021. The third dose resulted in an exponential increase in median anti-RBD-S1 IgG titer (P < 0.001), seroconversion rates (P < 0.001), and 50% vaccine efficacy rates (P < 0.001). According to ROC curve analysis, T helper and B cells were significantly associated with seroconversion responses at timepoint-1, whereas only B cells were relevant to 50% vaccine efficacy rates at timepoint-2. A positive linear correlation was shown between anti-RBD-S1 IgG titers and these lymphocyte subset counts. Multivariate analysis ruled out a potential role of T helper cells but confirmed a significant interaction between higher B cell levels and improved antibody response. These findings suggest that peripheral counts of B cells correlate with humoral response to the third dose of mRNA-BNT162b2 vaccine in actively treated cancer patients and could provide insights into a more comprehensive assessment of vaccination efficacy. |
| first_indexed | 2024-04-11T05:08:03Z |
| format | Article |
| id | doaj.art-e9d4174022ab40a593fe25e6eb7688c7 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-11T05:08:03Z |
| publishDate | 2022-12-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-e9d4174022ab40a593fe25e6eb7688c72022-12-25T12:16:33ZengNature PortfolioScientific Reports2045-23222022-12-0112111110.1038/s41598-022-25558-8Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patientsEnzo Maria Ruggeri0Fabrizio Nelli1Diana Giannarelli2Agnese Fabbri3Julio Rodrigo Giron Berrios4Antonella Virtuoso5Eleonora Marrucci6Marco Mazzotta7Marta Schirripa8Carlo Signorelli9Mario Giovanni Chilelli10Francesca Primi11Cristina Fiore12Valentina Panichi13Giuseppe Topini14Maria Assunta Silvestri15Medical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleBiostatistics Unit, Scientific Directorate, IRCCS, Fondazione Policlinico Universitario A. GemelliMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleMedical Oncology Unit, Department of Oncology and Hematology, Central Hospital of BelcolleCytofluorimetry Unit, Department of Oncology and Hematology, Central Hospital of BelcolleCytofluorimetry Unit, Department of Oncology and Hematology, Central Hospital of BelcolleDepartment of Oncology and Hematology, Microbiology and Virology Unit, Central Hospital of BelcolleAbstract The aim of this study was to evaluate the association of circulating lymphocytes profiling with antibody response in cancer patients receiving the third dose of COVID-19 mRNA-BNT162b2 vaccine. Immunophenotyping of peripheral blood was used to determine absolute counts of lymphocyte subsets, alongside detection of IgG antibodies against receptor-binding-domain (RBD) of the SARS-CoV-2 Spike protein (S1) before booster dosing (timepoint-1) and four weeks afterward (timepoint-2). An IgG titer ≥ 50 AU/mL defined a positive seroconversion response. An IgG titer ≥ 4446 AU/mL was assumed as a correlate of 50% vaccine efficacy against symptomatic infections. A total of 258 patients on active treatment within the previous six months were enrolled between September 23 and October 7, 2021. The third dose resulted in an exponential increase in median anti-RBD-S1 IgG titer (P < 0.001), seroconversion rates (P < 0.001), and 50% vaccine efficacy rates (P < 0.001). According to ROC curve analysis, T helper and B cells were significantly associated with seroconversion responses at timepoint-1, whereas only B cells were relevant to 50% vaccine efficacy rates at timepoint-2. A positive linear correlation was shown between anti-RBD-S1 IgG titers and these lymphocyte subset counts. Multivariate analysis ruled out a potential role of T helper cells but confirmed a significant interaction between higher B cell levels and improved antibody response. These findings suggest that peripheral counts of B cells correlate with humoral response to the third dose of mRNA-BNT162b2 vaccine in actively treated cancer patients and could provide insights into a more comprehensive assessment of vaccination efficacy.https://doi.org/10.1038/s41598-022-25558-8 |
| spellingShingle | Enzo Maria Ruggeri Fabrizio Nelli Diana Giannarelli Agnese Fabbri Julio Rodrigo Giron Berrios Antonella Virtuoso Eleonora Marrucci Marco Mazzotta Marta Schirripa Carlo Signorelli Mario Giovanni Chilelli Francesca Primi Cristina Fiore Valentina Panichi Giuseppe Topini Maria Assunta Silvestri Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients Scientific Reports |
| title | Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients |
| title_full | Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients |
| title_fullStr | Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients |
| title_full_unstemmed | Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients |
| title_short | Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients |
| title_sort | dynamic changes in peripheral lymphocytes and antibody response following a third dose of sars cov 2 mrna bnt162b2 vaccine in cancer patients |
| url | https://doi.org/10.1038/s41598-022-25558-8 |
| work_keys_str_mv | AT enzomariaruggeri dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT fabrizionelli dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT dianagiannarelli dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT agnesefabbri dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT juliorodrigogironberrios dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT antonellavirtuoso dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT eleonoramarrucci dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT marcomazzotta dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT martaschirripa dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT carlosignorelli dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT mariogiovannichilelli dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT francescaprimi dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT cristinafiore dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT valentinapanichi dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT giuseppetopini dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients AT mariaassuntasilvestri dynamicchangesinperipherallymphocytesandantibodyresponsefollowingathirddoseofsarscov2mrnabnt162b2vaccineincancerpatients |